PFIZER Australia and BioNTech have welcomed the Australian Register of Therapeutic Goods (ARTG) registration of the companies’ LP.8.1-adapted COVID-19 vaccine – Comirnaty LP.8.1 – for use in individuals six months and older.

Available in Australia from this month, supply of the new vaccine ensures its availability aligns with the anticipated seasonal spike in infections across the country.

The updated vaccine targets strains currently in circulation as recommended by independent global and regional health and regulatory bodies, with the LP.8.1 identified by the World Health Organization as one of the COVID-19 Variants under Monitoring (VUM).

COVID vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies.

Comirnaty is fully funded by the Australian Government for people aged over six months.

The post TGA approves new Comirnaty vax appeared first on Pharmacy Daily.